Related Experiment Videos
A Case of Pancreatic Cancer Complicated by Active Pulmonary Tuberculosis Successfully Managed through a
Kenta Tanaka1, Masaya Suenaga1, Mitsuru Tashiro1
1Department of Surgery, NHO Nagoya Medical Center, Nagoya, Aichi, Japan.
Introduction:
Pancreatic cancer complicated by active pulmonary tuberculosis (TB) presents a therapeutic dilemma because timely oncologic treatment must be balanced against infection control. Evidence guiding the curative-intent management of pancreatic cancer complicated by active TB remains extremely limited.
Case Presentation:
An 81-year-old man with a history of tuberculous peritonitis and diabetes mellitus presented with weight loss and poor glycemic control. Contrast-enhanced CT revealed a 14-mm pancreatic head tumor and multiple nodular lesions in the right upper lobe. Sputum examination was positive for acid-fast bacilli and Mycobacterium tuberculosis. After 4 weeks of initial 4-drug anti-TB therapy, sputum smear conversion and drug-susceptible TB were confirmed. Re-evaluation imaging revealed enlargement of the tumor to 21 mm with less than 180° portal vein abutment, and endoscopic US-guided fine-needle aspiration confirmed pancreatic ductal adenocarcinoma (PDAC). Although the tumor was anatomically resectable, active pulmonary TB was considered a host-related risk, and treatment was planned according to a strategy analogous to the International Association of Pancreatology concept of borderline resection on the basis of conditional factors. Following multidisciplinary discussion and shared decision-making with the patient, concurrent maintenance anti-TB therapy and 6 cycles of neoadjuvant gemcitabine plus nab-paclitaxel (GnP) were administered. The planned treatment was completed successfully without TB reactivation, resulting in a partial radiological response that permitted subtotal stomach-preserving pancreatoduodenectomy with portal vein resection. Histopathological examination revealed an R0 resection with a Grade 1b therapeutic response. After completing adjuvant chemotherapy, the patient developed a local recurrence 16 months after surgery but remained alive with stable disease under systemic chemotherapy 33 months after the initiation of anti-TB therapy, without TB reactivation.
Conclusions:
Although further accumulation of similar cases is needed, this case demonstrates that curative-intent treatment of PDAC complicated by active TB can be achieved through careful multidisciplinary management.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Chronic Pancreatitis II: Collaborative Care
Assessment: